Economic evaluation reveals cost-effectiveness challenges for biosimilar trastuzumab in HER2-positive breast cancer, highlighting the need for targeted price negotiations.
Although biosimilar trastuzumab has improved affordability, it remains not cost-effective at current prices. However, the relatively modest budget impact supports the feasibility of expanding access through targeted price negotiation and policy interventions. Threshold analysis indicated that price reductions to approximately THB 3700 per vial (1-year regimen) and THB 2950 per vial (until-progression regimen) would be required for trastuzumab to achieve cost-effectiveness under the Thai threshold.
No takes yet. Share an insight, caveat, or question.
Lochid-amnuay et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: